University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > Treatment > HIV Meds Quarterly > Winter 2010 > ARV Updates
Updates to the Database of ARV Drug Interactions
gray line
transparent gif
transparent gif

The following table summarizes recent additions to the HIV InSite Database of Antiretroviral Drug Interactions. For a full description of the updates, including references to the studies from which the data were derived, go to the database, click on a specific drug name, and search for the interacting agent.

New ARV Interactions (November 2009-March 2010)
Drug OneDrug TwoClinical EffectsMechanismsManagement
Source: McNicholl I. HIV InSite Database of Antiretroviral Drug Interactions. University of California San Francisco: Center for HIV Information; 2009
DarunavirBuprenorphineInhibition of CYP 3A4 by darunavir/ritonavirNo dosage adjustment necessary
DarunavirDigoxinMonitor digoxin level and adjust digoxin dosage based on clinical signs and digoxin level
DarunavirOmeprazoleNo dosage adjustment necessary
DarunavirRifabutinInhibition of CYP 3A4 by darunavir/ritonavirNo dosage adjustment necessary; potentially could use rifabutin 150 mg QOD
DarunavirWarfarin↓ warfarin effects (eg, ↓ INR, ↑ risk of clotting)Induction of CYP 3A4 by darunavirMonitor INR and adjust warfarin as indicated
EfavirenzLevonorgestrel↓ levonorgestrel effectsInduction of levonorgestrel metabolism by efavirenzUse backup form of birth control (eg, barrier)
EtravirineClopidogrelPossibly ↓ clopidogrel effectsActivation of clopidogrel to its active metabolites may be ↓ by etravirineAvoid combination; consider alternative agents
EtravirineFluconazole↑ etravirine effectsInhibition of CYP 3A4 by fluconazoleDosage adjustment not established
EtravirineLopinavir/ritonavirPotentially ↓ etravirine effectsPotential induction of CYP 3A4, 2C9, and 2C19 by lopinavir/ritonavirNo dosage adjustment necessary
EtravirineVoriconazolePossibly ↑ etravirine effectsInhibition of CYP 3A4 by voriconazoleNo dosage adjustment necessary
FosamprenavirPosaconazole↓ posaconazole and fosamprenavir efficacyDo not coadminister
IndinavirGinsengNo dosage adjustment necessary
Lopinavir/ritonavirBuprenorphineNo significant changeNo dosage adjustment necessary
Lopinavir/ritonavirNaloxoneNo significant changeNo dosage adjustment necessary
NevirapineLumefantrineUnknownNo dosage adjustment necessary
NevirapineTenofovirPotential early virologic failureUse caution when coadministering tenofovir, didanosine, and either efavirenz or nevirapine in treatment-naive patients
RaltegravirFamotidinePossibly owing to increased bioavailability because of ↑ gastric pHNo dosage adjustment necessary
Raltegravir
(400 mg BID)
Omeprazole
(20 mg QD)
Possibly owing to increased bioavailability because of ↑ gastric pHNo dosage adjustment necessary
Raltegravir
(400 mg Q12H)
Omeprazole
(20 mg QD x 4 days)
Possibly owing to increased bioavailability because of ↑ gastric pHNo dosage adjustment necessary

transparent gif